Imugene (IMU.AX) Aktsia Kursus
Imugene Kursus
Käive kasvas 55,4 % aastas viimase 18 aasta jooksul 4,40 M AUD-ni. Imugene netomarginaal on nüüd −1569,8 %, langenud −255,2 %-lt mõni aasta tagasi.
Imugene aktsiahinnad
Hangi need andmed Eulerpool API kaudu
100 000 päringut/kuus tasuta · krediitkaarti pole
Imugene ärimudel ja aktsia analüüs
Korduma kippuvad küsimused Imugene aktsia kohta
Imugene Ltd is a biotechnology company specializing in the development and commercialization of innovative immunotherapies for the treatment of various cancers. Their business model revolves around leveraging cutting-edge technologies and scientific expertise to create targeted and personalized immunotherapies that activate the body's own immune system to fight cancer. Imugene aims to improve patient outcomes and address the unmet medical needs in oncology by advancing their immunotherapy pipeline. With a focus on developing novel treatments and strategic partnerships, Imugene is dedicated to making a significant impact in the field of cancer immunotherapies.
Imugene Ltd is primarily active in the biotechnology industry.
The main competitors of Imugene Ltd in the market include major biopharmaceutical companies such as Merck & Co., Inc., Novartis AG, Bristol-Myers Squibb Company, and Pfizer Inc. These companies also specialize in developing innovative treatments and therapies for various diseases and disorders.
Imugene Ltd is a biopharmaceutical company dedicated to developing innovative immunotherapies to treat cancer. Founded in 1983, Imugene has a rich history in the field of oncology research and drug development. The company focuses on creating targeted immunotherapies that harness the power of the immune system to fight cancer cells. Imugene is committed to addressing unmet medical needs and improving patient outcomes. With a strong team of experienced scientists and a robust pipeline of promising drug candidates, Imugene aims to revolutionize cancer treatment and provide hope to patients worldwide. Imugene Ltd continues to strive towards its mission of developing much-needed advancements in the oncology field.
Imugene Ltd has achieved several significant milestones. The company successfully completed a Phase 1b study for its HER-Vaxx cancer immunotherapy in gastric cancer patients. Imugene also received approval from the US FDA to initiate its Phase 2 study for HER-Vaxx in gastric cancer. Additionally, Imugene has entered collaborations with renowned academic institutions, including City of Hope, to conduct preclinical and clinical trials for various cancer treatments. The company has made considerable progress in advancing its innovative immunotherapy pipeline, which shows great potential in the field of oncology. Imugene Ltd continues to strive for excellence and breakthroughs in cancer treatments.
Imugene Ltd is primarily present in Australia, United States, and Europe.
Imugene Ltd represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy, the company aims to revolutionize cancer treatment through its cutting-edge immunotherapy technologies. Imugene prioritizes scientific expertise and fosters strategic partnerships to advance its pipeline of novel and targeted therapies. The company's commitment to improving treatment outcomes for patients is evidenced by its emphasis on clinical development, rigorous research, and commercialization of innovative products. Imugene's inclusive approach promotes open communication and collaboration among researchers, clinicians, and industry experts, reinforcing its dedication to making a significant impact in the fight against cancer.
5 analüütikut hindavad praegu Imugene aktsiat: 4 soovitab osta, 1 hoida ja 0 müüa.
Praeguse kursiga kaubeldakse Imugene aktsiaga 0,02 EUR (0,03 AUD) juures.
Imugene aktsia (IMU.AX) on noteeritud 2 börsil, sh: ASX (IMU.AX).
Imugene Ltd is an Australian biopharmaceutical company that focuses on researching, developing, and marketing innovative therapeutic solutions for the treatment of cancer and infectious diseases. The company uses a unique technology platform to responsibly develop immuno-oncology products. Imugene is headquartered in Sydney, Australia, and has additional offices in the USA and Europe. The four main business areas of Imugene are: 1) Immuno-Oncology Products, 2) Immunomodulating Solutions in Cancer, 3) Infectious Diseases, and 4) Partner Programs. Imugene aims to expand its portfolio of immunotherapeutics through new product development and collaborations. It strives to revolutionize the treatment of cancer and infectious diseases with its unique technology platform and comprehensive portfolio of immunotherapeutics. Imugene is well-positioned to become a leading player in the biopharmaceutical industry with its presence in Australia, the USA, and Europe.
Käivet ei saa praegu Imugene kohta arvutada.
Imugene kasum on −105,34 M AUD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.
Võrdlusarvud hinna ja kasumiga (P/E) Imugene jaoks on praegu −0,11. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Imugene aktsia väärtust.
P/S-suhtarvu ei saa praegu Imugene kohta arvutada.
Eulpooli kvaliteedinäitaja Imugene jaoks on 4/10.
Imugene ISIN on AU000000IMU9. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.
Imugene WKN on 891460. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.
Imugene ticker on IMU.AX. Ticker-sümbol kasutatakse Imugene aktsiate kauplemiseks börsil.
Imugene aktsia
Imugene konkurendid
Imugene Börsiticker
Imugene FIGI
Kõik teised näitajad ja analüüsid Imugene kohta sügavamalt
Meie Imugene-aktsia analüüs sisaldab olulisi finantsnäitajaid, nagu käive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks käsitleme aspekte nagu aktsiad, turukapitalisatsioon, võlad, omakapital ja kohustused ettevõttes Imugene. Kui otsite nende teemade kohta põhjalikumat teavet, pakume teile meie alamlehtedel üksikasjalikke analüüse: